How does the planned biosimilar capacity scaling from 26,000 to 75,000 liters compare to peers, what is the associated dollar spend, and is it rightsized for future needs? Can you elaborate on the Q1 gross margin profile and the outlook for the remainder of the year and long-term with biosimilar integration?

The capacity expansion is perfectly sized and designed for flexibility, catering to the goal of filing a few biosimilars annually and commercial needs, including global supply diversification (U.S. and India). The spend for this expansion is $30M-$50M per year for the next 2-3 years. Q1 gross margin was a record at 510 bps up YoY, but sustainability at that level is challenging. Full-year 2026 gross margin is targeted at about 45%, up from 42.9% in FY25, driven by all business units. Long-term, gross margins are expected to reach closer to 47% over the next 3-4 years due to higher-priced biosimilars. “So I think we are positioned well to cater to all the 20 products that we have. And we have also considered this is as a global capacity. So it's not only U.S. subsidiary. We are playing globally in this market.”

Can you comment on the insider ownership of Kashiv? Why provide long-term revenue and EBITDA targets out to 2030? How much of the EBITDA margin expansion between 2027 and 2030 is due to the elimination of shared economics on biosimilars? What percentage of total revenue is expected from biosimilars by 2030?

Kashiv's insider ownership includes the Amneal Group, which has been transparently disclosed. Long-term guidance is provided due to high confidence in delivery, extensive diligence on the acquisition, and to provide a focal point for employees. The EBITDA expansion is a combination of existing business growth and the acquisition, with the base business already growing EBITDA at 10%. By 2030, biosimilars are expected to contribute $1 billion to $1.3 billion to total revenues of $4.3 billion to $4.5 billion. “So if you think about 2030, for example, the guidance we're providing is between $4.3 billion and $4.5 billion probably about $1 billion or a little over $1 billion, $1 billion to $1.3 billion. That's going to be biosimilars.”

How do you see the competitive landscape evolving in biosimilars, and will there be consolidation or fragmentation? Can you discuss the lanreotide opportunity for 2026, including market dynamics, competitive landscape, and its potential significance?

The biosimilar landscape will see vertically integrated players taking more market share, with a few key global players emerging. Amneal's vertically integrated platform, built over 10 years, provides a competitive advantage due to the high barriers to entry (R&D, manufacturing, IP). Large molecules may see 5-10 competitors, while niche molecules will have 2-3. Lanreotide presents a significant opportunity as a high-demand product with a market void due to a previous supplier's issues, leaving only the brand. Amneal is ready to supply upon FDA approval, and it's a complex drug-device combination product with global potential. “In lanreotide, Chris, is the market dynamics changed was a supplier in the market, had some contract manufacturing issues, so they are no longer in the market. It leaves it only with brand and the product is in high demand.”

AMRX

Amneal (AMRX) Q1 FY26 earnings call: guidance and Q&A

Earnings call· Mar 2026 (Q1 FY26)· Health Care· Apr 22, 2026

Source: earnings call transcript

Executive summary

Amneal Q1 FY26 — Kashiv BioSciences Acquisition and Strong Q1 Performance

Amneal Pharmaceuticals announced the strategic acquisition of Kashiv BioSciences, aiming to become a fully integrated global biosimilars leader and America's #1 affordable medicines company. This move, supported by strong Q1 FY26 results and raised full-year guidance, diversifies its portfolio and extends its growth profile well into the 2030s, leveraging Kashiv's R&D and manufacturing capabilities with Amneal's commercial engine.

Highlights

Q1 total net revenues grew 4% to $723 million.
Q1 adjusted EBITDA grew 19% to $202 million.
Q1 adjusted EPS grew 29% to $0.27.
Full-year 2026 stand-alone guidance was raised.
Net leverage ratio declined to 3.5x adjusted EBITDA in March 2026 from 3.9x in March 2025.

Concerns

Integration complexities of Kashiv BioSciences acquisition
Competitive landscape in biosimilars
Operational complexity of vertical integration in biosimilars
Gross margin normalization after strong Q1

Guidance & targets

Category	Target	Timeline	Confidence
Full-year 2026 stand-alone guidance	Raised high materiality	FY26	High
Combined company 2026 adjusted EBITDA and EPS outlook	Maintained higher outlook high materiality	FY26	High
Net debt leverage ratio	Below 3x adjusted EBITDA high materiality	FY28	High
2030 Revenues	Approximately $1.2 billion or 40% over 2026 high materiality	FY30	High
2030 EPS	Approximately $0.70 or 70% over 2026 high materiality	FY30	High
Affordable medicines revenue growth	7% to 8% medium materiality	FY26	High
Total company gross margin	About 45% high materiality	FY26	High
Total company gross margin	Closer to 47% high materiality	Next 3 to 4 years	Medium
Adjusted EBITDA	$820 million+ high materiality	FY27	High
Biosimilar drug substance capacity	75,000 liters medium materiality	FY28	High
Biosimilar development	3 to 5 biosimilars annually medium materiality	Annually	High
Commercial biosimilars	6 high materiality	FY27	High
Additional biosimilar approvals	6 or more high materiality	By 2030 · FY30	High
Lanreotide approval	Expected Q3 medium materiality	Q3 · FY26	High
Biosimilar Xolair approval	Anticipated year-end medium materiality	Q4 · FY26	High
Biosimilar approvals (ORENCIA, CIMZIA)	Additional approvals medium materiality	2028 and 2029	High

Segment performance

Segment	Revenue	YoY	QoQ	Margin
Affordable Medicines Revenue growth driven by strong performance of key women's health and ADHD products due to high market demand and increased Amneal supply. This segment's high-margin products drove the gross margin expansion. Segment gross margin: 47.3%Segment gross margin YoY change: up 320 basis points	$423 million	2%	—	47.3%
Specialty Strong growth driven by continued market uptake of CREXONT and rapid adoption of Brekiya for cluster headaches, confirming substantial market need and long-term revenue potential. CREXONT revenue: $21 millionBrekiya revenue: $4.6 million (vs $1.6 million in Q4 2025)	$133 million	23%	—	—
Healthcare (AvKARE) Revenue declined by $6 million as strong growth in the government channel was offset by an expected decline in the low-margin distribution channel, part of a strategy to enhance profitability. Gross margin YoY change: grew 690 basis points	$166 million	-4%	—	—

Deals & partnerships

Kashiv BioSciences Acquisition of Kashiv BioSciences to create a fully integrated global biosimilars leader, combining Kashiv's R&D and manufacturing capabilities with Amneal's commercial engine. $750 million upfront (50% cash, 50% equity) plus up to $350 million in contingent regulatory approval milestones and potential royalty over 12 years.

The upfront equity portion translates to approximately $29 million of Amneal shares, representing 8% equity dilution. Amneal will fund operations between signing and closing. The transaction requires Amneal's shareholder approval and customary closing conditions and regulatory approvals.

Pfizer GLP-1 collaboration for global markets, including rights to market Pfizer's branded products (from Metsera portfolio) in 18 emerging countries, including India.

This collaboration is part of Amneal's strategy to address the growing GLP-1 market and leverage a partnership model for international expansion.

Risks & headwinds

Integration complexities of Kashiv BioSciences acquisition Near-term

Not quantified

Mitigation:The combination builds on a long-standing partnership, significantly reducing execution risk. Capabilities are highly complementary.

Competitive landscape in biosimilars Long-term

Not quantified

Mitigation:Focus on vertical integration, building significant manufacturing and R&D infrastructure, and targeting niche molecules with fewer competitors. Leverage existing commercial relationships.

Operational complexity of vertical integration in biosimilars Long-term

Not quantified

Mitigation:Kashiv has spent 10 years and significant investment building the platform, which provides a competitive advantage. Amneal will bring its execution rigor to the platform.

Gross margin normalization after strong Q1 Remainder of FY26

Q1 gross margin up 510 bps YoY, sustainability hard to repeat

Mitigation:Expectation for full-year 2026 gross margin to be around 45%, still representing a 200 bps expansion over FY25, driven by all business units and portfolio evolution.

What to watch in Q2 FY26

Kashiv Acquisition Closing

Next quarter

Current Agreed, expected to close in a few months

Target Closed

Why it matters

The closing of the Kashiv acquisition is foundational to Amneal's biosimilar strategy and long-term growth targets.

Finally, we expect this highly strategic transaction to close in a few months as we work through Amneal's shareholder approval and customary closing conditions and regulatory approvals.

Find out whether AMRX delivers this. Inve re-checks your case every morning.

Q&A highlights

How will Amneal approach portfolio construction for the expanded biosimilar portfolio, considering the mix of mega-blockbusters and niche assets, and pharmacy vs. medical benefit drugs? What is the international biosimilar strategy? What are the 2-3 most exciting things about the new combined company that could drive upside to long-term guidance?

Amneal's biosimilar portfolio is well-thought-out, with a mix of large molecules (30%) like KEYTRUDA and DUPIXENT, and niche products (70%) with fewer competitors, all IP-driven. Commercialization in the U.S. will leverage existing relationships with major PBMs and customers. Internationally, the strategy is partnership-based, with India being an exception. Chirag expressed excitement about the core business's full throttle performance, the specialty brands (CREXONT, Brekiya), the Pfizer GLP-1 collaboration, and the biosimilars platform's potential to deliver 3-5 biosimilars annually.

“So if you -- this is why it's so important for Amneal to now have a complete platform, small molecule platform and large molecule platform.”

asked by Matt Dellatorre · answered by Chirag Patel

3 min read 6 chapters

Detailed narrative

Kashiv BioSciences Acquisition Rationale

Amneal Pharmaceuticals announced the strategic acquisition of Kashiv BioSciences to create a fully integrated global biosimilars leader, aiming to become the #1 affordable medicines company in the U.S. This transaction unlocks access to over $300 million of worldwide biologic loss of exclusivity over the next decade, leveraging Kashiv's deep R&D and manufacturing capabilities with Amneal's proven commercial scale.

The deal is structured with a balanced mix of $750 million upfront consideration (50% cash, 50% equity) and up to $350 million in performance-based milestones, maintaining a disciplined financial profile with a clear path to deleverage below 3x by 2028.

Biosimilar Platform Capabilities and Expansion

Kashiv brings over 12 years of biologics platform development, with more than $900 million invested, 600+ employees, and 4 R&D and manufacturing sites in the U.S. and India. This platform supports 3 to 5 biosimilar developments annually, offering end-to-end capabilities from clone development to regulatory execution.

Drug substance capacity is expected to scale from 26,000 liters in 2026 to 75,000 liters by 2028, with an annual capital expenditure of $30 million to $50 million for the next 2-3 years to achieve this expansion. This vertical integration is considered a competitive advantage, enabling faster execution and full economics.

Financial Outlook and Synergies

The highly synergistic transaction is expected to generate $400 million to $500 million in cumulative financial synergies over time. These synergies primarily stem from capturing full economics from previously partnered assets by eliminating milestones and profit-sharing obligations, as well as realizing substantial tax benefits and incentives from Indian authorities.

The combined company's net debt leverage ratio is projected to be 3.7x adjusted EBITDA at the end of 2026, with deleveraging expected to resume in 2027, targeting below 3x by 2028. Management expressed confidence in long-term targets, including 2030 revenues growing by approximately $1.2 billion (40%) and EPS by $0.70 (70%) over 2026.

Q1 FY26 Performance Highlights

Amneal reported strong preliminary Q1 FY26 results, characterized by robust top-line growth and exceptional bottom-line growth. Total net revenues reached $723 million, up 4% year-over-year. Adjusted EBITDA was $202 million, an increase of 19%, and adjusted EPS was $0.27, up 29%.

The Affordable Medicines segment saw revenue grow 2% to $423 million, driven by strong performance in women's health and ADHD products, with segment gross margin improving to 47.3% (up 320 basis points). Specialty revenue increased 23% to $133 million, with CREXONT revenue at $21 million and Brekiya at $4.6 million, demonstrating strong market uptake.

Long-Term Growth Strategy and Market Opportunity

The acquisition aligns with Amneal's long-term strategy to become a much larger, more diversified biopharmaceutical company by 2030, with over 400 retail and injectable medicines, 20+ biosimilars, and multiple specialty branded products. Management believes the industry is entering a 'golden era for biosimilars,' with the global market expected to grow from $40 billion today to $200 billion by 2035, driven by significant biologic loss of exclusivity.

Biosimilars are seen as the next major wave of affordable medicines, having saved the U.S. healthcare system an estimated $20 billion in 2024.

Biosimilar Portfolio and Near-Term Catalysts

The combined entity will have a portfolio of 20+ biosimilars targeting over $100 billion in U.S. opportunity. Key near-term catalysts include the expected Q3 approval of lanreotide, a high-value partner asset, and the anticipated year-end approval for biosimilar Xolair, which will now capture full value for Amneal.

The pipeline also includes additional approvals in 2028 and 2029 for biosimilars like ORENCIA and CIMZIA, representing meaningful future growth drivers. The portfolio is designed to be balanced and durable, including both large market opportunities and niche products with fewer competitors.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.